Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879178 | 1.00 | HCAR2 (0.56) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL23666175 | 0.84 | HCAR2 (0.54) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL30873909 | 0.83 | HCAR2 (0.52) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL1886588 | 0.83 | HCAR2 (0.59) | HCAR2MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL17285584 | 0.83 | HCAR2 (0.52) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL22428831 | 0.83 | HCAR2 (0.52) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL4184914 | 0.81 | HCAR2 (0.50) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL17518625 | 0.81 | HCAR2 (0.50) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL4194175 | 0.81 | HCAR2 (0.50) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL4194178 | 0.81 | HCAR2 (0.50) | HCAR2MAPTNPSR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| CN-117417355-A | Fused heterocyclic compound, preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230147833-A1 | OPTICALLY PURE OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230128062-A1 | AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9925204-B2 | Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation | KAWAI TOSHIHISA (US) | 2018-03-27 | — | — | US | disclosed |
| WO-1998003167-A1 | ISOBUTYLGABA AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN | WARNER-LAMBERT COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
| US-5710304-A | 5-METHYL-3((((4-METHYLPHENYL)SULFONYL)OXY)-METHYL)-HEXANOIC ACID ESTER CHEMICAL INTERMEDIATES | NORTHWESTERN UNIVERSITY (US) | 1998-01-20 | — | — | US | disclosed |
| US-5684189-A | HYDROLYZING AN AZIDE TO FORM AN INTERMEDIATE AZIDE, EXTRACTING THE INTERMEDIATE AZIDE INTO AN AQUEOUS BASE AND REDUCING THE AZIDE TO AN AMINE | NORTHWESTERN UNIVERSITY (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0641330-A4 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT. | UNIV NORTHWESTERN (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5608090-A | ANTICONVULSANTS | NORTHWESTERN UNIVERSITY (US) | 1997-03-04 | — | — | US | disclosed |
| US-5599973-A | REACTING ACID CHLORIDE WITH SUBSTITUTED 2-OXAZOLIDINONE AND BUTYLLITHIUM, THEN BENZYL ALPHA-BROMOACETATE, HYDROGEN PEROXIDE, LITHIUM OXIDE, SODIUM METABISULFITE, BORANE DIMETHYL SULFIDE, THEN TOSYLATION, AZIDE FORMATION, AMINATION | NORTHWESTERN UNIVERSITY (US) | 1997-02-04 | — | — | US | disclosed |
| US-5563175-A | GAMMAAMINOBUTYRIC ACID DERIVATIVE; NERVOUS SYSTEM DISORDERS | NORTHWESTERN UNIVERSITY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0641330-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023383-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1992009560-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147833-A1 | OPTICALLY PURE OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | WEE1, CYP51A1, CYP4F11 | HCAR2 1795/4885MAPT 3045/4885NPSR1 1495/4885 |
| US-20230128062-A1 | AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP4A11, CYP51A1, CYP4F11 | HCAR2 362/4885MAPT 4454/4885NPSR1 734/4885 |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | HCAR2 2348/4885MAPT 4871/4885NPSR1 3818/4885 |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | HCAR2 3800/4885MAPT 4332/4885NPSR1 4378/4885 |
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | HCAR2 1184/4885MAPT 4884/4885NPSR1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.